Lantern Pharma: Revolutionizing Oncology Treatment Development with Speed and Affordability

Dallas-based Lantern Pharma is disrupting the oncology treatment landscape by swiftly and affordably bringing potential therapies to patients. Despite having only 24 full-time employees, the precision medicine pharmaceutical company has three drugs in trial stages, showcasing its commitment to accelerating drug development. Led by CEO Panna Sharma, Lantern Pharma leverages big data and artificial intelligence to streamline the drug development process. Notably, their drug LP-284, targeting a rare form of non-Hodgkin’s lymphoma, obtained FDA orphan drug designation with minimal investment costs of $3 million. With the potential to serve tens of thousands of patients, Lantern Pharma's approach promises to deliver impactful treatments at unprecedented speed and accessibility, challenging conventional norms in the industry.